Wedbush analyst Laura Chico raised the firm’s price target on Vera Therapeutics (VERA) to $34 from $21 and keeps a Neutral rating on the shares. Overall, the Q4/2023 financial results report were largely as anticipated, the firm notes. Most notable, management reiterated timing guidance for ORIGIN 3 trial enrollment and potential topline data release. This year remains one of execution for Vera and in the near-term Wedbush also looks for updated RUBY-3 data from Alpine Immune Sciences (ALPN) to be presented at the WCN meeting.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERA:
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Vera Therapeutics reports FY23 EPS ($2.25) vs ($3.35) last year
- VERA Upcoming Earnings Report: What to Expect?
- Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
- Fly Insider: Skye Bioscience, Coinbase among week’s notable insider trades
